NCT01137136暂停不适用
Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea
适应症
试验速览
- 阶段
- 不适用
- 状态
- 暂停
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- The prevalence of CYP19 polymorphism
研究概览
简要总结
Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor. However, the incidence of variation of CYP19 in Korea has not known. Therefore, the investigators want to know the incidence of variation of CYP19 and to assess the effect of these variations of CYP19 to aromatase inhibitor users.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- — 至 80 Years（Child, Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •hormone receptor positiveBreast cancer patient
- •postmenopausal women
- •first user of aromatase inhibitor
排除标准
- •premenopausal
- •The patient who take the other antihormonal therapy
- •osteoporosis patients
结局指标
主要结局
The prevalence of CYP19 polymorphism
时间窗: 12. 31. 2011
次要结局
- The effect of CYP19 polymorphism to the prognosis of AI user(12. 31. 2016)
研究者
Seok Jin Nam
Professor, M.D., Ph.D.
Samsung Medical Center
研究点 (1)
Loading locations...
相似试验
终止
2 期
Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian FailureBreast CancerNCT00555477University of Michigan Rogel Cancer Center69
已完成
不适用
Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast CancerBreast CancerNCT00719966Mayo Clinic109
Unknown
2 期
Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled StudyMetastatic Breast CancerNCT04012918Ain Shams University124
招募中
不适用
Chronic Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast CancerNCT06776458University of Toronto112
已完成
不适用
Examining the Relationships Between Sleep, Fatigue, and Pain in Aromatase Inhibitor-treated PatientsBreast CancerNCT01983995University of Michigan49